Polymerized soluble venom-Human serum albumin

Roy Patterson; Irena M. Suszko; Leslie C. Grammer

doi:10.1016/0091-6749(85)90076-4

Polymerized soluble venom-Human serum albumin

Roy Patterson^*, Irena M. Suszko, Leslie C. Grammer

^*Corresponding author for this work

Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Extensive previous studies have demonstrated that attempts to produce polymers of Hymenoptera venoms for human immunotherapy resulted in insoluble precipitates that could be injected with safety but with very limited immunogenicity in allergic patients. We now report soluble polymers prepared by conjugating bee venom with human serum albumin with glutaraldehyde. The bee venom-albumin polymer (BVAP) preparation was fractionated on Sephacryl S-300 to have a molecular weight range higher than catalase. ¹²⁵I-labeled bee venom phospholipase A was almost completely incorporated into BVAP. Rabbit antibody responses to bee venom and bee venom phospholipase A were induced by BVAP. Human antisera against bee venom were absorbed by BVAP. No new antigenic determinants on BVAP were present as evidenced by absorption of antisera against BVAP by bee venom and albumin. BVAP has potential immunotherapeutic value in patients with anaphylactic sensitivity to bee venom.

Original language	English (US)
Pages (from-to)	382-387
Number of pages	6
Journal	The Journal of allergy and clinical immunology
Volume	75
Issue number	3
DOIs	https://doi.org/10.1016/0091-6749(85)90076-4
State	Published - Mar 1985

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/0091-6749(85)90076-4

Cite this

@article{fa046399c44149a793a0a6e5534b9690,

title = "Polymerized soluble venom-Human serum albumin",

abstract = "Extensive previous studies have demonstrated that attempts to produce polymers of Hymenoptera venoms for human immunotherapy resulted in insoluble precipitates that could be injected with safety but with very limited immunogenicity in allergic patients. We now report soluble polymers prepared by conjugating bee venom with human serum albumin with glutaraldehyde. The bee venom-albumin polymer (BVAP) preparation was fractionated on Sephacryl S-300 to have a molecular weight range higher than catalase. 125I-labeled bee venom phospholipase A was almost completely incorporated into BVAP. Rabbit antibody responses to bee venom and bee venom phospholipase A were induced by BVAP. Human antisera against bee venom were absorbed by BVAP. No new antigenic determinants on BVAP were present as evidenced by absorption of antisera against BVAP by bee venom and albumin. BVAP has potential immunotherapeutic value in patients with anaphylactic sensitivity to bee venom.",

author = "Roy Patterson and Suszko, {Irena M.} and Grammer, {Leslie C.}",

note = "Funding Information: From the Section of Allergy-Immunology, Department of Medicine, Northwestern University Medical School, Chicago, Ill. Supported by United States Public Health Service grant AI 11403 and the Ernest S. Bazley grant. Received for publication Nov. 4, 1983. Accepted for publication Aug. 1, 1984. Reprint requests: Roy Patterson, M.D., 303 E. Chicago Ave., Chi-cago, IL 60611.",

year = "1985",

month = mar,

doi = "10.1016/0091-6749(85)90076-4",

language = "English (US)",

volume = "75",

pages = "382--387",

journal = "The Journal of allergy and clinical immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "3",

}

TY - JOUR

T1 - Polymerized soluble venom-Human serum albumin

AU - Patterson, Roy

AU - Suszko, Irena M.

AU - Grammer, Leslie C.

N1 - Funding Information: From the Section of Allergy-Immunology, Department of Medicine, Northwestern University Medical School, Chicago, Ill. Supported by United States Public Health Service grant AI 11403 and the Ernest S. Bazley grant. Received for publication Nov. 4, 1983. Accepted for publication Aug. 1, 1984. Reprint requests: Roy Patterson, M.D., 303 E. Chicago Ave., Chi-cago, IL 60611.

PY - 1985/3

Y1 - 1985/3

N2 - Extensive previous studies have demonstrated that attempts to produce polymers of Hymenoptera venoms for human immunotherapy resulted in insoluble precipitates that could be injected with safety but with very limited immunogenicity in allergic patients. We now report soluble polymers prepared by conjugating bee venom with human serum albumin with glutaraldehyde. The bee venom-albumin polymer (BVAP) preparation was fractionated on Sephacryl S-300 to have a molecular weight range higher than catalase. 125I-labeled bee venom phospholipase A was almost completely incorporated into BVAP. Rabbit antibody responses to bee venom and bee venom phospholipase A were induced by BVAP. Human antisera against bee venom were absorbed by BVAP. No new antigenic determinants on BVAP were present as evidenced by absorption of antisera against BVAP by bee venom and albumin. BVAP has potential immunotherapeutic value in patients with anaphylactic sensitivity to bee venom.

AB - Extensive previous studies have demonstrated that attempts to produce polymers of Hymenoptera venoms for human immunotherapy resulted in insoluble precipitates that could be injected with safety but with very limited immunogenicity in allergic patients. We now report soluble polymers prepared by conjugating bee venom with human serum albumin with glutaraldehyde. The bee venom-albumin polymer (BVAP) preparation was fractionated on Sephacryl S-300 to have a molecular weight range higher than catalase. 125I-labeled bee venom phospholipase A was almost completely incorporated into BVAP. Rabbit antibody responses to bee venom and bee venom phospholipase A were induced by BVAP. Human antisera against bee venom were absorbed by BVAP. No new antigenic determinants on BVAP were present as evidenced by absorption of antisera against BVAP by bee venom and albumin. BVAP has potential immunotherapeutic value in patients with anaphylactic sensitivity to bee venom.

UR - http://www.scopus.com/inward/record.url?scp=0021831297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021831297&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(85)90076-4

DO - 10.1016/0091-6749(85)90076-4

M3 - Article

C2 - 3973313

AN - SCOPUS:0021831297

SN - 0091-6749

VL - 75

SP - 382

EP - 387

JO - The Journal of allergy and clinical immunology

JF - The Journal of allergy and clinical immunology

IS - 3

ER -

Polymerized soluble venom-Human serum albumin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this